APOE and diabetes mellitus: Even in non-diabetic apoE-deficient mice, sRAGE administration reduces plaque burden, albeit to a lesser extent than in diabetic models, underscoring the role of AGE–RAGE signaling in both diabetes-accelerated and basal atherosclerosis [24].